There is no published guidance on monitoring, no validated stopping rule, and no human safety threshold to reference
The main analyses of GLP-1-receptor agonists included 1,036,587 person-years of follow-up from 96,813 patients receiving GLP-1-receptor agonists (median [IQR] follow-up time, 4.4 [2.46.9] years) and 142,578 patients receiving sulfonylureas (median [IQR] follow-up time, 5.5 [3.28.1] years) during which 249 cholangiocarcinoma events occurred
Near-infrared light-responsive nanomaterials for cancer theranostics
Exogenous melatonin supplementation can suppress the pineal gland's own output over time
Mingrone G, Greco AV, Capristo E (febrero de 1999)
We further systematically evaluate the therapeutic potential of ferroptosis-targeting agents in promoting diabetic wound healing, thereby providing a theoretical framework for developing precision interventions against ferroptosis